Skip to main content

Edesa Biotech, Inc.

corporate_fare Company Profile

Edesa Biotech, Inc.

EDSA·NASDAQ·Life Sciences·CIK 0001540159

Edesa Biotech, Inc. is a biopharmaceutical company that develops treatments for inflammatory and immune-related diseases. The company focuses on acquiring, developing, and commercializing drug candidates based on mechanisms of action that have shown proof-of-concept in human subjects. Edesa Biotech prioritizes diseases with strong scientific rationale, no approved therapies or unmet medical needs, and large addressable market opportunities. The company's clinical pipeline is concentrated in two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa Biotech is developing EB06, an anti-CXCL10 monoclonal antibody candidate, for vitiligo, an autoimmune disorder causing skin depigmentation. CXCL10 is known to be involved in vitiligo, and its neutralization has prevented and reversed depigmentation in animal models. EB06 has shown a favorable safety and tolerability profile. Health Canada has approved a Phase 2 proof-of-concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo, and discussions are ongoing with the U.S. Food and Drug Administration (FDA) for the same study. Enrollment is anticipated to begin by midyear 2026, subject to regulatory approval. The Medical Dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), which is currently at the partnering stage. Edesa Biotech's most advanced Respiratory drug candidate is EB05 (paridiprubart), a Host-Directed Therapeutic (HDT) designed to modulate the body's immune response to infectious diseases or chemical agents. In October 2025, paridiprubart met primary and secondary endpoints with statistical significance, showing clinically meaningful improvement in survival and recovery, in a truncated Phase 3 clinical study of hospitalized patients with Acute Respiratory Distress Syndrome (ARDS). Paridiprubart is also being evaluated in an ongoing U.S. study.

Edesa Biotech, Inc. (NASDAQ:EDSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for EDSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for EDSA spans 8-K, SCHEDULE 13D/A, 424B5, 10-Q.

Recent high-impact activity:

  • Edesa Wins EU Orphan Designation for Paridiprubart in ARDS
  • Edesa Licenses Paridiprubart in Japan to Kyorin for $12M Upfront, Up to ~$134M Milestones
  • $12M Upfront, Up to $134M Milestones: Kyorin Licenses Edesa's ARDS Drug for Japan
  • Edesa Triples Executive Pay: CEO Salary to $657,423, CFO to $525,938
  • FDA Clears Edesa's IND for EB06 Vitiligo Phase 2; U.S. Enrollment Starts Next Quarter

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$7.19M
Op. Cash Flow
-$7.32M
Operating Income
-$7.91M
Cash & Equivalents
$10.79M
Debt / Equity
0.00×
Shares Outstanding
7.14M sh
Source: 10-K · filed 2025-12-12 · accession 0001171843-25-007914

Short Interest & Short Volume

4.02 days to cover

FINRA reported short interest of 158,091 shares in EDSA as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 37.7% of EDSA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)158,091 shares as of October 30, 2026
Change vs prior period▼ 2.0%
Days to cover4.02 at avg daily volume of 39,334
Daily short volume (FINRA facilities)37.7% of 47,799 shares on November 20, 2026
5-day average short volume39.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for EDSA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-20.

1 recent capital raise1 shelf registration

$25M Offering Priced at 17% Discount · Warrant Structure Adds Overhang

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with E →
$1.99 -0.50% today
52-week range · as of 2026-11-17 $0.72 – $20.32
Market cap
$27.02M
Volume
121.2K (0.0× avg)
3-mo avg 3M
Live data · 2026-11-21 18:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed EDSA - Latest Insights

EDSA
Nov 17, 2026, 9:25 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.94
Real-time Price: $1.99 info
Change: +$0.050 (+3%) info
Market Cap: $27.023M info
EDSA
Nov 09, 2026, 6:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.35
Real-time Price: $1.99 info
Change: -$0.360 (-15%) info
Market Cap: $27.023M info
EDSA
Nov 09, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.53
Real-time Price: $1.99 info
Change: -$0.5382 (-21%) info
Market Cap: $27.023M info
EDSA
Oct 23, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.77
Real-time Price: $1.99 info
Change: -$0.780 (-28%) info
Market Cap: $27.023M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.62
Real-time Price: $1.99 info
Change: -$0.630 (-24%) info
Market Cap: $27.023M info
EDSA
Oct 15, 2026, 9:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.84
Real-time Price: $1.99 info
Change: -$0.850 (-30%) info
Market Cap: $27.023M info
EDSA
Aug 25, 2026, 4:38 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $1.99 info
Change: -$2.46 (-55%) info
Market Cap: $27.023M info
EDSA
Aug 20, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $1.99 info
Change: -$2.53 (-56%) info
Market Cap: $27.023M info
EDSA
Aug 20, 2026, 4:10 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.52
Real-time Price: $1.99 info
Change: -$2.53 (-56%) info
Market Cap: $27.023M info
EDSA
Aug 19, 2026, 10:20 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $4.69
Real-time Price: $1.99 info
Change: -$2.70 (-58%) info
Market Cap: $27.023M info
EDSA
Aug 19, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $4.88
Real-time Price: $1.99 info
Change: -$2.89 (-59%) info
Market Cap: $27.023M info
EDSA
Aug 19, 2026, 4:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $1.99 info
Change: -$2.55 (-56%) info
Market Cap: $27.023M info
EDSA
Aug 13, 2026, 4:40 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.61
Real-time Price: $1.99 info
Change: -$3.62 (-65%) info
Market Cap: $27.023M info
EDSA
Aug 13, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.43
Real-time Price: $1.99 info
Change: -$3.44 (-63%) info
Market Cap: $27.023M info
EDSA
Jul 02, 2026, 5:00 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $7.50
Real-time Price: $1.99 info
Change: -$5.51 (-73%) info
Market Cap: $27.023M info
EDSA
Jun 16, 2026, 5:06 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $6.15
Real-time Price: $1.99 info
Change: -$4.16 (-68%) info
Market Cap: $27.023M info
EDSA
Jun 11, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.45
Real-time Price: $1.99 info
Change: -$3.46 (-63%) info
Market Cap: $27.023M info
EDSA
Jun 11, 2026, 9:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $1.99 info
Change: -$3.26 (-62%) info
Market Cap: $27.023M info
EDSA
Jun 05, 2026, 9:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.68
Real-time Price: $1.99 info
Change: -$5.69 (-74%) info
Market Cap: $27.023M info
EDSA
Jun 05, 2026, 9:20 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.62
Real-time Price: $1.99 info
Change: -$5.63 (-74%) info
Market Cap: $27.023M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets